CBLN4: A Potential Drug Target and Biomarker for Cerebellin-like Glycoprotein 1 (CGPS)

Target Name: CBLN4

NCBI ID: G140689

CBLN4

CBLN4: A Potential Drug Target and Biomarker for Cerebellin-like Glycoprotein 1 (CGPS)

Cerebellin-like glycoprotein 1 (CGPS) is a protein that is expressed in various tissues, including the brain, and is involved in the regulation of cell survival and differentiation. It has been implicated in a number of neurological and psychiatric disorders, including Parkinson's disease and schizophrenia. In addition, CGPS has also been shown to play a role in the development of certain types of cancer. As such, it is of great interest to study the function of CGPS and to identify potential drug targets or biomarkers for this protein.

CBLN4: A Putative Drug Target

The CBLN4 gene encodes a protein that is similar in structure to CGPS. CBLN4 has been shown to interact with several of the same protein-coding genes as CGPS, including those involved in cell adhesion, migration, and survival. This suggests that CBLN4 may have similar functions to CGPS, including a role in the regulation of cell survival and behavior.

In addition, CBLN4 has been shown to play a role in the development and progression of certain types of cancer. For example, studies have shown that CBLN4 is highly expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. This suggests that CBLN4 may be a useful biomarker for these cancers, and that targeting CBLN4 may be a promising strategy for the development of new cancer therapies.

CBLN4: A Potential Biomarker

In addition to its potential as a drug target, CBLN4 may also be a useful biomarker for certain types of cancer. For example, CBLN4 has been shown to be expressed in a variety of tissues and cells, including cancer cells, which suggests that it may be a reliable indicator of the presence of cancer. Additionally, CBLN4 has been shown to be involved in the regulation of cell survival and behavior, which may be relevant to the regulation of cancer cell growth and progression.

In addition to its potential as a biomarker, CBLN4 may also be involved in the development of certain types of cancer. For example, studies have shown that CBLN4 is highly expressed in a variety of tissues and cells, including cancer cells, which suggests that it may be a useful indicator of the risk of certain types of cancer. Additionally, CBLN4 has been shown to play a role in the regulation of cell survival and behavior, which may be relevant to the regulation of cancer cell growth and progression.

Conclusion

Cerebellin-like glycoprotein 1 (CGPS) is a protein that is involved in the regulation of cell survival and behavior. The CBLN4 gene encodes a protein that is similar in structure to CGPS, and has been shown to interact with several of the same protein-coding genes as CGPS. In addition, CBLN4 has been shown to play a role in the development and progression of certain types of cancer, and may be a useful biomarker for these conditions. As such, CBLN4 is of great interest as a potential drug target or biomarker for the treatment of a variety of neurological and psychiatric disorders, as well as certain types of cancer.

Protein Name: Cerebellin 4 Precursor

Functions: Acts as a synaptic organizer in specific subsets of neurons in the brain (By similarity). Essential for the formation and maintenance of inhibitory GABAergic synapses (By similarity). Promotes the development of dendrite-targeting inhibitory GABAergic synapses made by somatostatin-positive interneurons (By similarity). May contribute to the function of ventral medial habenula region of the brain implicated in the regulation of anxiety-related behaviors (By similarity). May play a role in CBLN3 export from the endoplasmic reticulum and secretion (By similarity)

The "CBLN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBLN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets